A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

Operating Margin
ABL Bio Inc

-146.6%
Current
-288%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-146.6%
=
Operating Profit
-35.8B
/
Revenue
24.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
KR
ABL Bio Inc
KOSDAQ:298380
1.3T KRW
-147%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.7B EUR
-22%
Country KR
Market Cap 1.3T KRW
Operating Margin
-147%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.3B USD
Operating Margin
28%
Country US
Market Cap 141.6B USD
Operating Margin
19%
Country US
Market Cap 115.3B USD
Operating Margin
38%
Country US
Market Cap 102.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 77.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35.7B EUR
Operating Margin
-22%
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-146.6%
=
Operating Profit
-35.8B
/
Revenue
24.4B
What is the Operating Margin of ABL Bio Inc?

Based on ABL Bio Inc's most recent financial statements, the company has Operating Margin of -146.6%.